Evidence map›Paper›PMID 40255076›Full record

ArticleGut microbes2025

Distinct clusters of bacterial and fungal microbiota in end-stage liver cirrhosis correlate with antibiotic treatment, intestinal barrier impairment, and systemic inflammation.

Laura Buttler, David A Velázquez-Ramírez, Anja Tiede, Anna M Conradi, Sabrina Woltemate, Robert Geffers, Birgit Bremer, Vera Spielmann, Julia Kahlhöfer, Anke R M Kraft and 6 more

Abstract read
In one paragraph

Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Laura ButtlerDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
David A Velázquez-RamírezInstitute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.
Anja TiedeDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Anna M ConradiInstitute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.
Sabrina WoltemateInstitute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.
Robert GeffersGerman Center for Infection Research (DZIF), Hannover-Braunschweig, Germany.
Birgit BremerDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Vera SpielmannDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Julia KahlhöferDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Anke R M KraftDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Dirk SchlüterInstitute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.
Heiner WedemeyerDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Markus CornbergDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
Christine FalkGerman Center for Infection Research (DZIF), Hannover-Braunschweig, Germany.
Marius VitalInstitute for Medical Microbiology and Hospital Epidemiology, Hannover Medical School, Hannover, Germany.ORCID 0000-0003-4185-3475
Benjamin MaasoumyDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-3250-3177

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Decompensated liver cirrhosis (dLC) is associated with intestinal dysbiosis, however, underlying reasons and clinical consequences remain largely unexplored. We investigated bacterial and fungal microbiota, their relation with gut barrier integrity, inflammation, and cirrhosis-specific complications in dLC-patients. Competing-risk analyses were performed to investigate clinical outcomes within 90 days. Samples were prospectively collected from 95 dLC-patients between 2017 and 2022. Quantitative metagenomic analyses clustered patients into three groups (G1-G3) showing distinct microbial patterns. G1 (

Indexed as

Anti-Bacterial AgentsBacteriaEnd Stage Liver DiseaseFungiGastrointestinal MicrobiomeInflammationLiver CirrhosisMycobiomeAdultAgedDysbiosisFemaleHumansIntestinal MucosaMaleMetagenomicsAnti-Bacterial Agentscirrhosis-related complicationsdysbiosisfungigut barrierIntestinal microbiomeleaky gutliver cirrhosismetagenomicssystemic inflammation

Identifiers

PMID40255076
PMCPMC12054929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.